Czechia

The primary regulatory authority for health products in Czechia is the State Institute for Drug Control (SÚKL), which operates under the Ministry of Health and oversees the authorization, supervision, and pharmacovigilance of pharmaceuticals, medical devices, diagnostics, and increasingly digital health solutions. The principal governing legislation includes Act No. 378/2007 Coll. on Pharmaceuticals, Act No. 375/2022 Coll. implementing EU medical device regulations, and a suite of EU-level instruments including Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR). As a European Union member state, Czechia fully participates in the European Medicines Agency (EMA) centralized procedure for innovative medicines, while nationally authorized products follow SÚKL's decentralized or mutual recognition pathways. Medical devices must bear CE marking under the applicable EU regulation, with conformity assessment conducted by notified bodies prior to market placement.

Submission requirements for nationally authorized pharmaceuticals follow the Common Technical Document (CTD) format, aligned with ICH guidelines and EMA standards. Applicants must designate a local Marketing Authorization Holder (MAH) or an EU-based representative with a registered address in the Czech Republic or another EU member state. Recent reforms have focused on transposing and enforcing the MDR and IVDR frameworks, strengthening post-market surveillance obligations, and integrating digital health applications (DiGAs-equivalent frameworks are still evolving at national level). SÚKL has also enhanced its pharmacovigilance infrastructure in alignment with EMA's good pharmacovigilance practice (GVP) modules. Parallel to SÚKL, the Institute of Health Information and Statistics (ÚZIS) plays a growing role in digital health data governance.

Public procurement of health products in Czechia is primarily coordinated through the Ministry of Health, which oversees state-funded hospitals and healthcare institutions, and through the General Health Insurance Company (Všeobecná zdravotní pojišťovna, VZP) and other statutory health insurers that collectively reimburse the majority of pharmaceutical and medical device expenditure. Reimbursement decisions for pharmaceuticals are governed by Act No. 48/1997 Coll. on Public Health Insurance, with SÚKL conducting health technology assessment (HTA)-informed reimbursement reviews. Public hospitals and regional health authorities procure medical devices and diagnostics through public tenders governed by Act No. 134/2016 Coll. on Public Procurement, which mandates transparent, competitive bidding processes. Central framework agreements are sometimes used for high-volume consumables and diagnostics, coordinated at the national or regional level through the Ministry of Health or individual hospital networks.

The private healthcare sector in Czechia represents a meaningful share of procurement activity, particularly for diagnostic equipment, digital health tools, and premium pharmaceuticals not reimbursed under the statutory system. Private clinics and diagnostic laboratories procure independently through commercial channels and distributor agreements. Czechia is a high-income EU member state and does not typically rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi for mainstream health product categories. However, EU Structural Funds and Horizon Europe grants have supported capital investment in hospital infrastructure, digital health interoperability projects, and research-oriented procurement. There are no formal local manufacturing preference policies enshrined in procurement law, though EU-level discussions on strategic health autonomy and supply chain resilience may influence future policy direction.